Department of Pharmacy, Integral University, Dasauli, Lucknow, India.
Department of Pharmacy, Goel Institute of Pharmaceutical Sciences, Lucknow, India.
Drug Res (Stuttg). 2022 Oct;72(8):424-434. doi: 10.1055/a-1867-4654. Epub 2022 Jun 27.
Ovarian cancer is characterized by the establishment of tolerance, the recurrence of disease, as well as a poor prognosis. Gene signatures in ovarian cancer cells enable cancer medicine research, therapy, prevention, & management problematic. Notwithstanding advances in tumor puncture surgery, novel combinations regimens, and abdominal radiation, which can provide outstanding reaction times, the bulk of gynecological tumor patients suffer from side effects & relapse. As a consequence, more therapy alternatives for individuals with ovarian cancer must always be studied to minimize side effects and improve progression-free and total response rates. The development of cancer medications is presently undergoing a renaissance in the quest for descriptive and prognostic ovarian cancer biomarkers. Nevertheless, abnormalities in the BRCA2 or BRCA1 genes, a variety of hereditary predispositions, unexplained onset and progression, molecular tumor diversity, and illness staging can all compromise the responsiveness and accuracy of such indicators. As a result, current ovarian cancer treatments must be supplemented with broad-spectrum & customized targeted therapeutic approaches. The objective of this review is to highlight recent contributions to the knowledge of the interrelations between selected ovarian tumor markers, various perception signs, and biochemical and molecular signaling processes, as well as one's interpretation of much more targeted and effective treatment interventions.
卵巢癌的特征是建立耐受、疾病复发以及预后不良。卵巢癌细胞的基因特征使癌症药物研究、治疗、预防和管理变得复杂。尽管肿瘤穿刺手术、新的联合治疗方案和腹部放疗取得了进展，可以提供出色的反应时间，但大多数妇科肿瘤患者都受到副作用和复发的困扰。因此，必须不断研究卵巢癌患者的更多治疗选择，以最小化副作用并提高无进展生存期和总反应率。目前，癌症药物的开发正在复兴，以寻找描述性和预后性卵巢癌生物标志物。然而，BRCA2 或 BRCA1 基因的异常、多种遗传倾向、不明原因的发病和进展、分子肿瘤多样性以及疾病分期都可能影响这些指标的反应性和准确性。因此，目前必须补充广谱和定制的靶向治疗方法。本综述的目的是强调最近在了解选定的卵巢肿瘤标志物、各种感知标志以及生化和分子信号转导过程之间的相互关系方面的贡献，以及对更有针对性和更有效的治疗干预的解释。
